NCT07271251已完成3 期
A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Participants With Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 267
- 试验地点
- 15
- 主要终点
- Change in glycated haemoglobin (HbA1c).
研究概览
简要总结
The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the new tablet formulation being tested in this study. The study will last approximately 27 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- •Japanese male or female.
- •Age 18 years or above at the time of signing the informed consent.
- •Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥) 90 days prior to day of screening.
- •Glycated haemoglobin (HbA1c) of 7.0-10.5 percent (%) (53-91 millimoles per mole [mmol /mol]) (both inclusive) at screening.
- •Stable daily dose(s) ≥ 60 days before screening with any 1-2 of the following oral antidiabetic drugs (OADs): Sulfonylurea (SU), glinide, thiazolidinedione (TZD), alpha-glucosidase inhibitor (α-GI), sodium-glucose cotransporter 2 (SGLT-2) inhibitor or metformin (effective or maximum tolerated dose as judged by the investigator) according to Japanese labelling.
排除标准
- •Known or suspected hypersensitivity to study intervention(s) or related products.
- •Previous participation in this study. Participation is defined as signed informed consent.
- •Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- •Current participation (i.e., signed informed consent) in any other interventional clinical study.
- •Exposure to an investigational medicinal product within 90 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
- •Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.
- •Previous or planned (during the study period) obesity treatment with surgery or a weight loss device.
- •Anticipated initiation or change in concomitant medications for more than 14 consecutive days affecting weight or glucose metabolism.
- •Use of any medication with unknown or unspecified content within 90 days before screening.
- •Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
- •Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.
- •History or presence of pancreatitis (acute or chronic).
- •History of major surgical procedures involving the stomach potentially affecting absorption of study products or current presence of gastrointestinal implant.
- •Myocardial infarction, stroke, transient ischaemic attack or hospitalization for unstable angina pectoris within 60 days before screening.
- •Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening.
- •Planned coronary, carotid or peripheral artery revascularisation.
- •Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified within 90 days before screening or in the period between screening and randomisation.
- •Impaired liver function, defined as Alanine Aminotransferase (ALT) ≥ 2.5 times or Bilirubin >1.5 times upper normal limit at screening.
- •Renal impairment with estimated glomerular filtration rate (eGFR) less than (<) 30 millilitres per minute per meter square (mL/min/1.73 m^2) as per 2021 Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI) formula (by creatinine) at screening.
- •Treatment with medication for diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- •Presence or history of malignant neoplasms or in situ carcinomas within 5 years before screening.
- •Any episodes of diabetic ketoacidosis within 90 days before screening.
研究组 & 干预措施
Oral semaglutide
Experimental
Participants will receive oral semaglutide once daily.
干预措施: Oral semaglutide (Drug)
Oral semaglutide D
Experimental
Participants will receive oral semaglutide D once daily.
干预措施: Oral semaglutide (Drug)
结局指标
主要结局
Change in glycated haemoglobin (HbA1c).
时间窗: From baseline (week 0) to end of treatment (week 20)
Measured in percentage (%)-point.
次要结局
- Change in body weight(From baseline (week 0) to end of treatment (week 20))
- Change in body weight(From baseline (week 0) to end of treatment (week 20))
- Number of treatment emergent adverse events (TEAEs)(From baseline (week 0) to end of study (week 25))
研究者
研究点 (15)
Loading locations...
相似试验
招募中
4 期
The Impact of Semaglutide Compared to Energy Restriction on Type 2 DiabetesSemaglutideType 2 Diabetes Mellitus (T2DM)Caloric RestrictionNCT07272343Second Affiliated Hospital of Nanchang University100
终止
4 期
Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle CareDiabetes Mellitus, Type 2Glucose Metabolism Disorders (Including Diabetes Mellitus)NCT04938388Sansum Diabetes Research Institute12
招募中
3 期
A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer's diseaseMild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type2023-506825-13-00Novo Nordisk A/S13
已完成
1 期
Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy MenDiabetes Mellitus, Type 2NCT03638778Novo Nordisk A/S105
进行中（未招募）
不适用
Phase 2 study of oral semaglutide tablet for patients with Parkinson's diseaseParkinson's diseasejRCT205123009099